Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis

Cover Page

Abstract

Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federation, registration certificate number ЛП-005439 from 04.04.2019. This article outlines the first 12-week results of a phase III clinical trial in patients with psoriasis.

Materials and methods. The BCD-085-7 study (PLANETA) is a comparative, randomized, double-blind, placebo-controlled phase 3 clinical study of the efficacy and safety of netakimab in patients with moderate-to-severe plaque psoriasis. This review presents the results of the first 12 weeks. The study is ongoing at the moment, the total duration of treatment for each patient is 3 years (154 weeks). Patients were randomized in a ratio of 2:2:1 into one of three arms: group 1 received netakimab subcutaneously at a dose of 120 mg once a week for the first three weeks (induction) and then once every 2 weeks up to week 10, group 2 received netakimab subcutaneously at a dose of 120 mg once a week for the first three weeks (induction) and then once every 4 weeks up to week 10, group 3 received a placebo subcutaneously on day 1 at weeks 0, 1, 2, 4, 6, 8 10. In order to maintain a double-blind design, placebo was administered to patients in group 2 at weeks 4 and 8.

Results. Both netakimab groups showed a significant superiority over placebo (p < 0.001) and the absence of statistically significant differences between the two regimens of therapy (p > 0.05) across all endpoints. PASI 75 at week 12 was reached by 77.65 % of patients using netakimab once every 2 weeks and 83.33 % of patients using netakimab once every 4 weeks (ITT population). The rate of clear and almost clear skin (sPGA 0–1) was reached by 81.18 and 79.76 % of patients using netakimab once every 2 weeks and once every 4 weeks, respectively. The safety assessment showed no statistically significant differences between the groups, the incidence rate of adverse events in netakimab arms was not higher than in the placebo arm. There were no cases of early withdrawal due to adverse events and cases of grade 4 toxicity according to CTCAE 4.03. During the 12 weeks of the study, one serious adverse event was registered in group 2 (pneumonia grade 3), which was recovered without any consequences. The immunogenicity assessment showed binding antibodies formation at week 12 in one patient who received BCD-085 every 2 weeks. Neutralizing antibodies were not detected. Conclusion. Netakimab showed high efficacy in the treatment of psoriasis, more than 80 % of patients achieved PASI 75 and sPGA 0–1 (clear and almost clear skin) by the week 12 of treatment. The drug showed a favorable safety profile and low immunogenicity. Based on the study results the regimen once a week during the first 3 weeks (induction), then once every 4 weeks was chosen for medical use in patients with psoriasis.

About the authors

A. A. Kubanov

State Research Center of Dermatovenereology and Cosmetology, Ministry of Health of the Russian Federation

Email: fake@neicon.ru
Alexey A. Kubanov — Dr. Sci. (Med.), Prof., RAS Corresponding Member, Leading Researcher of the Dermatology Department Russian Federation

A. L. Bakulev

Saratov State Medical University named after V. I. Razumovsky, Ministry of Health of the Russian Federation

Email: fake@neicon.ru
Andrey L. Bakulev — Dr. Sci. (Med.), Prof., Head of the Department of Dermatology and Cosmetology Russian Federation

A. V. Samtsov

S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Email: fake@neicon.ru
Alexey V. Samtsov — Dr. Sci. (Med.), Prof., Head of the Department of Skin and Venereal Diseases Russian Federation

V. R. Khairutdinov

S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Email: fake@neicon.ru
Vladislav R. Khairutdinov — Dr. Sci. (Med.), Assoc. Prof. of the Department of Skin and Venereal Diseases Russian Federation

E. V. Sokolovskiy

Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation

Email: fake@neicon.ru
Evgeny V. Sokolovskiy — Dr. Sci. (Med.), Prof., Head of the Department of Dermatology and Venereology with a Hospital Russian Federation

M. M. Kokhan

Ural Research Institute for Dermatovenerology and Immunopatology

Email: fake@neicon.ru
Muza M. Kokhan — Dr. Sci. (Med.), Prof., Head of the Scientific Clinical Department of Dermatology Russian Federation

A. V. Artemyeva

BIOCAD company

Author for correspondence.
Email: artemevaav@biocad.ru
Antonina V. Artemyeva — Medical Expert; tel.: +7 (911) 110-39-34 Russian Federation

E V. Chernyaeva

BIOCAD company

Email: fake@neicon.ru
Ekaterina V. Chernyaeva — Director for R&D in the Field of Rheumatology and Dermatology Russian Federation

R. A. Ivanov

BIOCAD company

Email: fake@neicon.ru
Roman A. Ivanov — Cand. Sci. (Med.), Deputy General Director for Biomedical R&D Russian Federation

References

  1. Michalek I. M., Loring B., John S. M. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212.
  2. Поликарпов А. В., Александрова Г. А., Голубев Н. А., Тюрина Е. М., Оськов Ю. И., Шелепова Е. А. Заболеваемость всего населения России в 2017 году. Статистические материалы. Часть 1. М., 2018. 140 c. [Polikarpov A. V., Aleksandrova G. A., Golubev N. A., Tyurina E. M., Os’kov Yu. I., Shelepova E. A. The incidence rate of the entire population of Russia in 2017. Statistical data. Part 1. Moscow, 2018. 140 p. (In Russ.)]
  3. Maul J.-T., Navarini A. A., Sommer R., Anzengruber F., Sorbe C., Mrowietz U. et al. Gender and age significantly determine patient needs and treatment goals in psoriasis — a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–708.
  4. Самцов А. В., Хайрутдинов В. Р., Бакулев А. Л., Кубанов А. А., Карамова А. Э. и др. Эффективность и безопасность препарата BCD085 — оригинального моноклонального антитела против интерлейкина-17 у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Результаты II фазы международного многоцентрового сравнительного рандомизированного двойного слепого плацебо-контролируемого клинического исследования. Вестник дерматологии и венерологии. 2017;5:52– 63. [Samtsov A. V., Khairutdinov V. R., Bakulev A. L., Kubanov A. A., Karamova A. E. et al. Efficacy and safety of BCD-085, a novel IL-17 inhibitor. Results of phase II clinical trial in patients with moderate-to-severe plaque psoriasis. Vestn Dermatol Venerol. 2017;5:52–63 (In Russ.)]
  5. Об обращении лекарственных средств: Федеральный закон от 12 апр. 2010 г. № 61-ФЗ. [Federal Law of the Russian Federation on the Circulation of Medicines No. 61-FZ dated April 12, 2010 (In Russ.)]
  6. FDA, Guidance for Industry S6 Addendum to Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. 2012. https://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM194490.pdf
  7. World Health Organization, Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. 2013. https://www.who.int/biologicals/biotherapeutics/rDNA_ DB_final_19_Nov_2013.pdf
  8. Common Terminology Criteria for Adverse Events (CTCAE) v4.3, U.S. Department of health and human services, 2010.
  9. Nast A., Amelunxen L., Augustin M., Boehncke W. H. et al. S3 Guideline for the treatment of psoriasis vulgaris, update — Short version part 1 — Systemic treatment. J Dtsch Dermatol Ges. 2018;16(5):645–669.
  10. Gisondi P., Altomare G., Ayala F., Bardazzi F. et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
  11. Coates L. C., Murphy R., Helliwell P. S. New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol. 2016;174(6):1174–1178.
  12. Абдулганиева Д. И., Бакулев А. Л., Белоусова Е. А., Знаменская Л. Ф. и др. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018;12(3):4–18. [Abdulganieva D. I., Bakulev A. L., Belousova E. А., Znamenskaya L. F. et al. Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn’s disease). Modern Rheumatology Journal. 2018;12(3):4–18 (In Russ.)]
  13. Bissonnette R., Luger T., Thaci D., Toth D. et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514.
  14. Langley R. G., Kimball A. B., Nak H., Xu W. et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):333–339.
  15. Jullien D., Prinz J. C., Nestle F. O. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol. 2015;135(1):31–38.
  16. Samtsov A. V., Khairutdinov V. R., Bakulev A. L., Korotaeva T. V. et al. Long-term efficacy and safety of a novel IL17-inhibitor in moderate-to-severe plaque psoriasis: E-Poster. 27th EADV Congress Paris, France. 2018.

Statistics

Views

Abstract: 2306

PDF (Russian): 763

Cited-by

CrossRef: 9

  1. Savvina N, Sleptsova N, Steshenko I. Experience of using the domestic inhibitor IL (anti-IL-17A) in the treatment of moderate-severe psoriasis. Klinicheskaya dermatologiya i venerologiya. 2020;19(5):739. doi: 10.17116/klinderma202019051739
  2. Mazurov VI, Erdes SF, Gaydukova IZ, Dubinina TV, Pristrom AM, Kunder EV, et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA. Modern Rheumatology Journal. 2020;14(4):39. doi: 10.14412/1996-7012-2020-4-39-49
  3. Olisova OY, Anpilogova EM. Systemic treatment of psoriasis: from methotrexate to biologics. Vestnik dermatologii i venerologii. 2020;96(3):7. doi: 10.25208/vdv1162
  4. Kruglova LS, Hotko AA. Choice of first-line genetically engineered biological drugs for moderate and severe psoriasis in patients with comorbid pathology. Medical alphabet. 2020;(24):18. doi: 10.33667/2078-5631-2020-24-18-22
  5. Korotaeva TV, Mazurov VI, Lila AM, Gaydukova IZ, Bakulev AL, Samtsov AV, et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. Rheumatology Science and Practice. 2020;58(5):480. doi: 10.47360/1995-4484-2020-480-488
  6. Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opinion on Emerging Drugs. 2020;25(2):89. doi: 10.1080/14728214.2020.1745773
  7. Kruglova LS, Korotaeva TV. Medical and social care program for patients with psoriasis and/or psoriatic arthritis eligible for biological dmards in real clinical practice. Rheumatology Science and Practice. 2020;58(5):495. doi: 10.47360/1995-4484-2020-495-502
  8. Korotaeva TV, Mazurov VI, Lila AM, Gaydukova IZ, Bakulev AL, Samtsov AV, et al. Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study. Rheumatology Science and Practice. 2021;59(1):47. doi: 10.47360/1995-4484-2021-47-55
  9. Wolkenstein P, Zaslavsky D, Sobolev AV, Skrek S, Yunovidova A, Vasiliev N, et al. Psoriatic triADA, or lost clinical response. Klinicheskaya dermatologiya i venerologiya. 2020;19(6):935. doi: 10.17116/klinderma202019061935

Article Metrics

Metrics Loading ...

Dimensions

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c)



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies